MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 263 filers reported holding MIRATI THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.48 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $136,602,679 | +120465.1% | 3,135,966 | 0.0% | 87.83% | +6.0% |
| Q2 2023 | $113,302 | -99.9% | 3,135,966 | 0.0% | 82.86% | +1.8% |
| Q1 2023 | $116,595,216 | -17.9% | 3,135,966 | 0.0% | 81.37% | -0.1% |
| Q4 2022 | $142,090,619 | -35.1% | 3,135,966 | 0.0% | 81.47% | +2.9% |
| Q3 2022 | $219,016,000 | +4.0% | 3,135,966 | 0.0% | 79.20% | +4.5% |
| Q2 2022 | $210,517,000 | -18.4% | 3,135,966 | 0.0% | 75.77% | +11.4% |
| Q1 2022 | $257,839,000 | -43.9% | 3,135,966 | 0.0% | 68.01% | -9.1% |
| Q4 2021 | $460,015,000 | -17.1% | 3,135,966 | 0.0% | 74.86% | -4.4% |
| Q3 2021 | $554,784,000 | +9.5% | 3,135,966 | 0.0% | 78.28% | +11.8% |
| Q2 2021 | $506,553,000 | -5.7% | 3,135,966 | 0.0% | 69.99% | -2.0% |
| Q1 2021 | $537,191,000 | -22.0% | 3,135,966 | 0.0% | 71.40% | +5.9% |
| Q4 2020 | $688,784,000 | +32.3% | 3,135,966 | 0.0% | 67.42% | -0.6% |
| Q3 2020 | $520,727,000 | +45.4% | 3,135,966 | 0.0% | 67.85% | +21.8% |
| Q2 2020 | $358,033,000 | +48.5% | 3,135,966 | 0.0% | 55.71% | +1.4% |
| Q1 2020 | $241,062,000 | -34.6% | 3,135,966 | +9.6% | 54.92% | -8.6% |
| Q4 2019 | $368,664,000 | +50.9% | 2,860,966 | -8.8% | 60.11% | +4.6% |
| Q3 2019 | $244,323,000 | -24.4% | 3,135,966 | 0.0% | 57.48% | -14.9% |
| Q2 2019 | $323,004,000 | +40.5% | 3,135,966 | 0.0% | 67.56% | +34.0% |
| Q1 2019 | $229,866,000 | +72.8% | 3,135,966 | 0.0% | 50.43% | +20.2% |
| Q4 2018 | $133,028,000 | -9.9% | 3,135,966 | 0.0% | 41.94% | +6.4% |
| Q3 2018 | $147,704,000 | -4.5% | 3,135,966 | 0.0% | 39.41% | +57.0% |
| Q2 2018 | $154,603,000 | +60.6% | 3,135,966 | 0.0% | 25.10% | -35.7% |
| Q1 2018 | $96,274,000 | +68.2% | 3,135,966 | 0.0% | 39.06% | +16.5% |
| Q4 2017 | $57,231,000 | +69.8% | 3,135,966 | +8.9% | 33.52% | +91.3% |
| Q3 2017 | $33,704,000 | +220.4% | 2,880,702 | -0.0% | 17.52% | +164.2% |
| Q2 2017 | $10,519,000 | -29.8% | 2,881,702 | 0.0% | 6.63% | -5.1% |
| Q1 2017 | $14,985,000 | +58.4% | 2,881,702 | +44.7% | 6.99% | -23.5% |
| Q4 2016 | $9,462,000 | -28.1% | 1,992,085 | 0.0% | 9.13% | -90.9% |
| Q3 2016 | $13,168,000 | +21.1% | 1,992,085 | 0.0% | 100.00% | +1069.5% |
| Q2 2016 | $10,877,000 | -67.4% | 1,992,085 | +28.9% | 8.55% | -63.3% |
| Q1 2016 | $33,328,000 | +101.9% | 1,546,001 | +195.9% | 23.32% | +28.8% |
| Q4 2015 | $16,511,000 | – | 522,500 | – | 18.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $116,595,216 | 81.37% |
| ORACLE INVESTMENT MANAGEMENT INC | 201,400 | $7,488,052 | 7.25% |
| Paradigm Biocapital Advisors LP | 1,396,779 | $51,932,243 | 4.92% |
| Octagon Capital Advisors LP | 750,000 | $27,885,000 | 4.01% |
| Boxer Capital, LLC | 2,000,000 | $74,360 | 3.65% |
| Artal Group S.A. | 1,537,709 | $57,172 | 3.40% |
| Avoro Capital Advisors LLC | 5,555,555 | $206,555,535 | 3.06% |
| RTW INVESTMENTS, LP | 3,643,114 | $135,450,979 | 2.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 244,000 | $9,071,920 | 2.53% |
| Kynam Capital Management, LP | 499,853 | $18,584,535 | 2.40% |